Boosting Tumor Immunotherapy by Bioactive Nanoparticles via Ca ²⁺ Interference Mediated TME Reprogramming and Specific PD‐L1 Depletion

Adv. Funct. Mater. 2022, 32, 2201275 DOI: 10.1002/adfm.202201275 The authors regret a mistake in the results of HMGB1 in the Figure S13A in Supporting Information of the above article. The correct version of Figure S13A (Supporting Information) is shown below. This correction does not affect any discussion and conclusions of “Immunofluorescence staining, and immunohistochemistry of the tumor sections verified the CRT exposure and HMGB1 release in vivo (Figure S13A, Supporting Information)” reported in the paper.